MedTrace Logo

Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery

NCT01174719 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2015-04-08

No results posted yet for this study

Summary

The aim of the study is to compare three different regimens for volume replacement during cardiac surgery, e.g. Albumin 5%, Hydroxyethylstarch 130/0.4 (HES) and Ringer-Lactate (RL).

Main Outcome parameters: chest tube drainage and coagulation parameters. The investigators hypothesis is that HES is as safe as Albumin, however less expensive. Whether RL is an even less expensive and as safe alternative has to be shown.

Conditions

Interventions

DRUG

volume replacement

Hydroxyethylstarch up to 50mL/kg/24 hrs

DRUG

Humanalbumin 5%

Humanalbumin 5% up to 50 mL/kg/24 hours

DRUG

volume replacement

up 10 50mL/kg/24 hours

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Eva M Base, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2010-02-28
Completion
2010-04-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01174719 on ClinicalTrials.gov